Benefits and Pensions Monitor’s Post

Exploring the impact of Hidradenitis Suppurativa on career trajectories and workplace dynamics. Novartis Pharmaceutical Canada Inc. discusses the challenges and importance of early treatment access. https://hubs.la/Q02GmZ4Z0 #ChronicCondition #WorkplaceImpact #Healthcare #NovartisCanada

Exploring the impact of Hidradenitis Suppurativa on career trajectories and workplace dynamics. Novartis Pharmaceutical Canada Inc. discusses the challenges and importance of early treatment access. https://hubs.la/Q02FmrpV0 #ChronicCondition #WorkplaceImpact #Healthcare #NovartisCanada

𝗖𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝗛𝗼𝗿𝗺𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝗲𝗽𝘁𝗶𝘃𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟮. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The report offers an overview of the Combined Hormonal Contraceptives industry chain's development, detailing the market status of Hospital Pharmacy and Retail Pharmacy across different age brackets. It assesses key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, applications, and market trends within the Combined Hormonal Contraceptives sector. Regionally, North America and Europe exhibit steady growth propelled by government initiatives and rising consumer awareness, whereas the Asia-Pacific region, notably China, leads the global market due to strong domestic demand, supportive policies, and robust manufacturing. The report provides a comprehensive understanding of the Combined Hormonal Contraceptives market, offering insights into industry dynamics, trends, challenges, and opportunities for stakeholders. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗖𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝗛𝗼𝗿𝗺𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝗲𝗽𝘁𝗶𝘃𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁.𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d-edJxXK *𝗕𝘆 𝗧𝘆𝗽𝗲: 15-24 years,  25-34 years,  35-44 years,  Above 44 years *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospital Pharmacy,  Retail Pharmacy,  Online Pharmacy *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Actavis,  Agile Therapeutics,  Allergan,  Bayer,  Teva Pharmaceuticals,  ANI Pharmaceuticals,  Ortho-McNeil-Janssen Pharmaceuticals,  Noven Pharmaceuticals,  Johnson & Johnson,  Mylan #combinedhormonalcontraceptives #contraception #birthcontrol #womenshealth #contraceptivetechnology #hormonalcontraception #familyplanning #reproductivehealth #contraceptivepills #contraceptiveoptions #healthcare #pharmaceuticals #contraceptiveindustry #contraceptivemarket #contraceptiveproducts #contraceptiveusage #hormonaltherapy #healthandwellness #contraceptivesafety #healthcaremarket

Such an interesting article on women’s health and in particular menopause within the pharmaceutical industry, seems inevitable that this part of the market will be heavily invested in considering the vast amount of women it affects (450 million+). 🧬 Very surprising to see how little development there has been in funding this area over the years, and how most of the development has stayed outside of PLC’s. As the headline suggests, if developed right its could be a $350 bn market, let’s hope it gets the attention it deserves over the coming years. 💰 Hopefully with more knowledge and mainstream attention we can finally get the desired outcome for women.🤞 #womenshealth #pharmanews #pharmaceutical #usa https://lnkd.in/eA3MxEtM

Ozempic, a brand name for semaglutide, is a prescription drug created by Novo Nordisk approved in 2017 by the FDA for managing type 2 diabetes due to its efficacy in controlling blood sugar levels. Although initially intended for diabetes management, studies revealed that users also experienced weight loss in addition to glucose management, but it is currently not approved as a weight loss drug. Doctors can prescribe Ozempic off-label for weight loss for people with a BMI higher than 30, or higher than 27 if they have other obesity-related co-morbidities. Many other similar drugs on the market lead to weight loss, including Wegovy, Mounjaro, Trulicity, and many more GLP-1-based medications. Women are significantly more likely to use weight loss drugs like Ozempic. A study from Michigan Medicine showed that the percentage of young adult women using these drugs increased by 659% from 2020-2023, compared to a 481% increase among young adult men. Despite this, there are major information gaps regarding how these medications uniquely impact female patients. Many healthcare professionals have voiced concerns about the lack of data on these drugs’ effects during pregnancy. Although the drug is not recommended for pregnant women, given that approximately 45% of pregnancies in the U.S. are unplanned, there is a possibility of continued use of semaglutides during pregnancy. Many women have experienced unexpected pregnancies while taking weight loss medications like Ozempic, leading to the term “Ozempic babies.” Although no research has confirmed the cause, some suspect weight loss from these medications can help restore ovulation and improve fertility. Currently, no studies have been published on the relationship between Ozempic and birth control. However, medical professionals have voiced concerns because Ozempic slows gastric emptying, potentially impacting the effectiveness of birth control pills if the hormones are not absorbed completely. #womenshealth #femtech #healthtech #digitalhealth #healthcare #healthcareinnovation #startups #innovation #health #medtech #healthcareresearch #femalehealth #genderhealthgap #reproductivehealth #venturecapital #vc #funding #investment #grants #maternalhealth #periods #menstruation #sexualhealth #sextech #menopause #fertility #pregnancy #postpartum #eggfreezing #IVF #healthequity #pelvicfloor #pelvicfloorhealth #hormonehealth

I look forward to the day when "hallucinogen use" is not the term applied to psychedelics, and when research does not bundle this into the same category as "cigarettes, sedatives, and non-medical use of opioid medications." Interesting information, however: "Among adults aged 19 to 30, 8% reported past-year use of hallucinogens, significantly higher than five years ago (5% in 2017) and 10 years ago (3% in 2012). Types of hallucinogens reported by participants included LSD, MDMA, mescaline, peyote, shrooms or psilocybin, and PCP. Most of past-year use in 2022 reported by adults in this age group involved hallucinogens other than LSD (7% in 2022). Past-year hallucinogen use reached historically high prevalence among adults 35 to 50 years old, reported by 4% in 2022. The prevalence reported in 2022 was also a substantial increase compared to the year before (2% in 2021) and five and 10 years ago (no greater than 1% in both 2017 and 2012)."

Female Contraceptives Market Anticipates Gradual Growth Over the Next Decade, says Report of Global Data Female contraceptives market, forecasting a modest 0.5% compound annual growth rate (CAGR) from $7.8 billion in 2022 to $8.2 billion in 2032. In a recent report on Female Contraceptives Market, published on 19 December by GlobalData, a renowned data and analytics company, projections for the female contraceptives market across the seven major markets (7MM) (US, France, Germany, Italy, Spain, the UK and Japan) indicate a marginal growth at a compound annual growth rate (CAGR) of 0.5%. The market is expected to inch up from $7.8 billion in 2022 to $8.2 billion in 2032. Oral contraceptives are poised to maintain their stronghold, driving this modest growth over the next decade. Read more below 👇 #newsupdate #pharmaceuticals #business #updates #latestnews #contraceptive #sales #global #globaldata

Opioid-Induced Respiratory Depression represents a critical burden due to its potential to cause life-threatening breathing difficulties in individuals using opioids. This condition poses substantial challenges in healthcare settings, demanding constant vigilance to prevent respiratory failure. Addressing this burden necessitates a multifaceted approach involving enhanced monitoring, education, and alternative pain management strategies. To overcome the existing challenges, pharma and biotech companies such as Atelerix Life Sciences, Enalare Therapeutics Inc., and others are actively working on novel pharmacological approaches to mitigate the risk of Opioid-Induced Respiratory Depression, easing the burden in treatment and patient safety. Get a more detailed analysis, at: https://lnkd.in/gm2k3a-9 #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast

OxyContin: Balancing Pain Relief and Potential Misuse 💊 Introduction: Today, let's explore a controversial yet impactful case study - OxyContin's formulation. Developed to address pain relief, this opioid has sparked debates surrounding ethics and misuse. Join me as we delve into the lessons learned in striking a delicate balance. #OxyContin #FormulationEthics 📚 Background: OxyContin, an extended-release form of oxycodone, entered the market as a potent analgesic for chronic pain management. However, its formulation raised concerns due to its potential for misuse and addiction. ⚖️ Balancing Act: The challenge in formulating OxyContin lay in providing effective pain relief while minimizing the risk of misuse and addiction. Striking this balance required careful consideration of factors like release rate, dosage form, and patient safety. 🤔 Formulation Challenges: Extended-Release Dynamics: Designing a controlled-release formulation to provide sustained pain relief without facilitating immediate euphoria or overdose. Abuse-Deterrent Properties: Incorporating features to deter misuse, such as resistance to crushing or dissolving for alternative administration routes. 🛠️ Lessons Learned: Educational Initiatives: The OxyContin case emphasizes the importance of educating healthcare professionals, patients, and the public about the risks associated with opioid medications. Regulatory Response: The formulation challenges prompted regulatory bodies to develop guidelines for abuse-deterrent formulations, shaping future opioid developments. ⚠️ Impact and Controversy: Despite its initial success in pain management, OxyContin's controversy stems from its contribution to the opioid epidemic. The case underscores the need for a comprehensive approach to pain management, including non-opioid alternatives. 🌐 Moving Forward: The OxyContin case serves as a pivotal moment in pharmaceutical formulation, highlighting the ongoing responsibility to balance therapeutic benefits with potential risks. As we move forward, it shapes the ethical considerations in designing medications for pain relief. #OxyContin #FormulationEthics #PharmaInsights  #PharmaJourney #CollaborativeInnovation #UnmetMedicalNeeds #HealthcareInnovation #MedicalResearch #GlobalHealth #usfda #ushealthcare #ResponsiveDelivery #PrecisionMedicine #TargetedTherapies #PolymerDrugConjugates #BiodegradablePolymers #SustainablePharma #PharmaInnovation #DrugDelivery #Innovation #genericdrugs #PharmaceuticalScience #FormulationExcellence #RegulatoryCompliance #PharmaceuticalSupplyChain #FutureOfPharma #formulationdevelopment #pharmaceuticalindustry #pharmaceuticalmanufacturing #pharmaceuticalinnovation #pharmanews #scienceinnovation #sciencenews #fdaregulations #mhra #fda #healthcanada #emea #healthcare #researchanddevelopment #businessdevelopment